Actively Recruiting
Safety and Effectiveness Study of BAY 3771249 Alone or With Cetuximab in Advanced or Metastatic Colorectal Cancer with KRAS G12D Mutation
Led by Bayer · Updated on 2026-10-05
130
Participants Needed
21
Research Sites
49 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new treatment for people with advanced or metastatic colorectal cancer CRC who have a specific mutation called KRAS G12D. This mutation is associated with fewer treatment options and a poorer outlook. The study focuses on how safe and tolerable the investigational drug BAY 3771249 is, how the body processes it, and whether it can help shrink or control tumors in these patients. The trial is open-label and includes participants who have already tried other cancer treatments. Participants will receive BAY 3771249 either alone or combined with another drug called cetuximab. The study starts with a dosage escalation phase to find the highest safe dose, followed by a dosage expansion phase where more participants receive the determined dose until disease progression or unacceptable side effects occur. Treatments are given orally for BAY 3771249 and by intravenous infusion for cetuximab. Throughout the study, researchers will monitor changes in lab tests and vital signs, track any side effects including dose-limiting toxicities, and assess tumor response using standard criteria. Pharmacokinetic measurements such as drug concentration over time will be collected. Participants health will be followed for up to two years, and those benefiting from treatment may continue BAY 3771249 after the study ends. The trial could help develop new options for patients with this cancer mutation.
CONDITIONS
Brief Title
A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation
Research Team
B
Bayer Clinical Trials Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here